BioSpace News Archive

SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced it will report financial results for the second quarter of 2020 after market close on Monday, August 3, 2020.

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release second quarter 2020 financial and operating results prior to market open on Tuesday, August 4, 2020. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time

AnHeart Therapeutics, Co., Ltd . (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, today announced that the first patient has been dosed with taletrectinib in a Phase 2 trial of Non-Small Cell Lung Cancer (NSCLC) with ROS1 fusion at Shanghai Pulmonary Hospital. “We have laid out an ambitious timeline for the taletrectinib global clinical development program for TKI-naïve and -pr

Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Jeff Poulton has been appointed to the Board of Directors. Mr. Poulton is the Chief Financial Officer at Alnylam. Mr. Poulton brings 25 years of experience to Homology’s Board of Directors, including leading finance, business development and commercial ope

Argonaut Manufacturing Services, a contract manufacturing organization serving the life sciences, molecular diagnostics, and biopharma industries, announced that they have completed an expansion of their Viral Transport Media filling capabilities for COVID-19 testing.

Dr. Michael Mina of the Harvard T. Chan School of Public Health announced the successful enrollment of the first 500 patients just 10 days after launching a COVID-19 longitudinal serological surveillance study using TrialSpark’s Covalence trial platform.

New Position Marks Continued Demand for Telehospitalists and Nocturnists in the Inpatient Sector

Detailed results of colonoscopist- and investigator-blinded phase 2B trial of ECP, a good-tasting, easy-to-consume prep released 93.8% of patients treated with ECP achieved a colonoscopy rating of Excellent or Good, compared to 83.9% of those using standard prep Phase 3 study planned to initiate in Q1 2021 More ‘patient-friendly,’ palatable prep could help increase patient acceptance of colonoscopies for colorectal cancer scre

ReShape Lifesciences Inc., (OTCQB:RSLS) announced today that in recognition of National Parents’ Day, it is providing updated information resources for women considering pregnancy that want to safely lose excess weight and experience the joy of parenthood.

NK AWS-S200™ Performs Difficult Intubations in Less Than Half the Time of Other Devicesi